VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Feb. 15, 2007) - Med BioGene Inc. (TSX VENTURE:MBI), a biotechnology company developing genetic biomarkers to improve screening, diagnosis, prognosis and treatment decisions for patients suffering from certain cancers and cardiovascular disease, is pleased to announce that it has entered the development phase for its genetic screening test for colorectal cancer (CRC).
